Peginterferon lambda

BIOLOGICAL2 trials

Sponsors

Nanogen Pharmaceutical Biotechnology Joint Stock Company, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Chronic Hepatitis DeltaHepatitis C

Phase 1

The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

CompletedNCT02063607

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyHepatitis C

Start: 2013-12-31End: 2016-07-31Updated: 2016-12-15

Phase 2

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

WithdrawnNCT05953545

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Chronic Hepatitis Delta

Start: 2024-05-22End: 2024-05-22Updated: 2024-05-23